Overview
Gain up-to-date insights into promising biologic and immunomodulating treatments, including dupilumab, barzolvolimab, and remibrutinib. This session focuses on translating emerging Phase 3 evidence into practical, individualized decision-making to optimize patient care.
Moderator: Dr. Sendhil Kumaran
India
Welcome and Introduction
Dr. Sendhil Kumaran
(2 min)
TALK 1: Dupilumab in Urticaria
Mechanisms, Efficacy, and Clinical Experience
Dr. Pavel Kolkhir | Germany
(12 min)
TALK 2: Remibrutinib for Chronic Urticaria
A New BTK Inhibitor
Assoc. Clin. Prof. Dr. Hermenio Lima | Canada
(12 min)
TALK 3: Barzolvolimab in Urticaria
Targeting Mast Cells for Long-Lasting Control
Dr. Melba Munoz | Germany
(12 min)
TALK 4: Choosing the Right Treatment
From Omalizumab to Emerging Options
Prof. Dr. Simon Francis Thomsen | Denmark
(12 min)
Discussion and Q&A
All Faculty | Moderated by Dr. Sendhil Kumaran
(8 min)
Closing Remarks
Dr. Sendhil Kumaran
(2 min)
